A plan in the United States to make it easier to access certain unproven peptide drugs is opposed by most Food and Drug Administration (FDA) scientific staff, according to people familiar with the policy’s development. The effort is linked to US Health Secretary Robert F. Kennedy Jr. and is described as covering some injectable peptides promoted in the wellness sector.
Several outlets report that the policy went through regulatory review at the White House before publication, and that FDA drug staff members raised concerns it could weaken the agency’s role in keeping unproven products off the market. The guidance would direct the FDA not to take enforcement action against certain specialty pharmacies selling specific peptides that have not undergone the agency’s safety and effectiveness review.
Coverage also highlights the context for the peptides involved, including that some occur naturally in the body and that drug companies have previously brought related peptides to market as medications. Outlets specifically mention examples such as BPC-157 and TB-500, promoted for injury healing and muscle building, with discussion that both are considered doping substances by international sports authorities. Where provided, outlets differ mainly in emphasis on staffing opposition and the enforcement approach rather than on the core facts reported.
